

**ANTIFOLATE ADVISORY PANEL**

**Minutes of Meeting**

**March 16, 1998**

**Ixtapa, Mexico**

**CONFIDENTIAL**

Panel Participants

Carmel Allegra  
Robert Allen  
Joseph Bertino  
Hilary Calvert  
James Carmichael  
Karin Mattson  
Enrico Mini  
Jean Louis Misset  
Herbie Newell  
Peter O'Dwyer  
Louis Paz-Ares  
Hans Schmoll

Panel Discussion Leader

Jackie Walling (Lilly)

Investigator Participants

Stephen Clarke


Lilly Attendees

Marilyn Arnett, Johannes Blatter, Victor Chen, Stephen Clarke, Dawn Gardner, Steve Hamburger, Kim Hartsock, Constanza Ilardi, Robert Johnson, Louis Kayitalire, Diana Kelley, Sean McCarthy, Mark Miller, Katrina Nelson, Robin Nelson-Rice, Steve Nicol, Clet Niyikiza, Angela Panadero, Angela Ribecco, Michael Scott, Julia Stickland, Adrian Thomas, Jerry Thompson, Don Thornton, Donna Watts

cc of minutes: Rick Schilsky, Dan Von Hoff, meeting participants, MTA Product Team



CONFIDENTIAL



AV00008671

**MINUTES OF MEETING:**

The primary objectives of this meeting were to obtain input from the Panel on the fastest route to MTA registration, and to consider the prioritization of the ongoing and planned clinical trials. These objectives were related to the mission/vision/strategic intent statements for the project. These statements include speed to market as the initial registration objective with parallel development of several indications in different clinical settings as a means of accomplishing this objective, and maximizing the value of MTA in the treatment of cancer. Activity of MTA has been demonstrated in a number of areas, and there are insufficient resources to bring all of the possibilities forward to registration at this time.

Discussion focused on NSCLC, breast cancer, mesothelioma, cervical cancer, head and neck cancer, bladder cancer, renal cancer, and pancreatic cancer. Generally, discussion for each indication was initiated with a marketing overview, followed by clinical data, clinical plans and development/registration strategies.

**Non-Small cell lung cancer (NSCLC)**

*Marketing*

Market research data from the U.S. [Redacted] on the incidence and treatment of 1<sup>st</sup> and 2<sup>nd</sup> line NSCLC were provided by Lilly. These data were approximately one year old and involved a data base of 60 physicians (20 patients per physician) in each country.

[Redacted]

[Redacted] Other drugs that may be used at the time of an MTA launch could be capecitabine and CPT-11. Taxotere is available in Europe and is being used in NSCLC, although not currently approved for this indication.

***NSCLC 2<sup>nd</sup> line - Clinical Studies/Plans***

An approach that is being considered by Lilly to achieve rapid registration involves Phase 2/3 studies in 2<sup>nd</sup> line NSCLC. If this option does not accomplish a speed-to-market objective, these studies may not be pursued at this time.

A Phase 2 study (JMBR) in patients who have received one prior chemotherapy regime with or without platinum has been initiated (Europe), but it is too early to provide response data. Another proposed study (JMBQ, U.S.) in platinum/taxane failures is planned. This latter study is designed as a pivotal U.S. registration study, with the objective of determining MTA activity in a 2<sup>nd</sup> line setting, gaining speed to registration

through a single Phase 2/3 study, and asking if vitamin supplementation has an effect on the toxicity of MTA in this group of patients.

Panel input to this study design was requested. The following summarizes recommendations from that discussion:

1. The suggested Phase 2/3 study design compares MTA, MTA + vitamins (vitamins are 1 mg folic acid, 25 mg B6, and 2 mg B12), and Navelbine. In the initial phase II portion of the study response rate will be used as the hurdle and TTP will be the primary endpoint of the study. There was considerable debate about the design of the study, and Jim Carmichael felt that it might be premature, given our understanding of the toxicity of the compound. Peter O' Dwyer felt that the interim hurdle should be based on TTP also.
2. The MTA dose of 600 mg/m<sup>2</sup>, decreasing if necessary, rather than starting with the 500 mg/m<sup>2</sup> was recommended. To date, there is no evidence of a clinical dose-response relationship between the 500 mg/m<sup>2</sup> and 600 mg/m<sup>2</sup> dosage levels. However, it also is too early to conclude that there is no clinical difference between the two dosages.
3. Pharmacokinetic studies (real time) were suggested to expand our knowledge of MTA's toxicity profile.
4. If a minimum response rate is achieved in the MTA- and MTA/vitamin-treated patients (a 10% response rate in the 2 arms combined), a decision of which of the two MTA arms to carry forward into a standard Phase 3 study will be determined on the basis of the relative toxicity profiles between the two arms. The decision making criteria need to be defined up front in the protocol.
5. There will be balancing of patients in this study for prognostic factors (e.g. performance status, homocysteine levels, investigator sites) so that the treatment effect can be evaluated. Approximately 540 patients will be enrolled in the Phase 2/3 study.
6. Navelbine was the recommended comparator, although there was considerable concern about obtaining signed informed consents/IRB approvals in a study involving Navelbine since this drug is not approved for 2<sup>nd</sup> line NSCLC and has been shown to be inactive in 2<sup>nd</sup> line in terms of response rates. It was pointed out, however, that no chemotherapeutic agent currently is approved in 2<sup>nd</sup> line, and that Navelbine is used routinely at some stage of a patient's disease (U.S. mentioned specifically), with a substantial number of patients deriving benefit (e.g. improvement of symptoms). It will be important to utilize a comparator that offers effective treatment, even if is this comparator is not approved. The choice of the comparator as well as other protocol parameters will be discussed with the FDA when the Phase 2/3 development plans are reviewed.
7. The endpoints agreed to by the Panel were time to progression as the primary endpoint, with an index of palliation (e.g. clinical benefit, quality of life) and median duration of survival as secondary endpoints. Response rates were not considered critical, nor a good surrogate for palliation.

The estimate of enrolling 540 patients in 1 year for the above study was considered reasonable in view of the Panel's and Lilly's experiences. The first patient visit was estimated as June, 1998 with a U.S. submission/approval in Q400/Q301 (assuming that necessary safety data for selection of an MTA arm and efficacy data are available and that enrollment into the Phase 3 portion of the study will not be delayed.)

The Panel felt that there currently was insufficient information to know the activity of MTA in 2<sup>nd</sup> line NSCLC, and agreed that additional studies in this patient population were warranted.

***NSCLC 1st line - Clinical Studies/Plans***

Lilly's two Phase 2 studies (chemonaive, Stage 3 and 4) have indicated response rates of 23%, median survival 9.2 months (JMAO, n=30) and 17%, median survival 7.5 months\* (JMAL, n=35) (\*these data are heavily censored, with several patients remaining on study). Another Phase 2 study in NSCLC (JMAY) involves combination cisplatin (75 mg/m<sup>2</sup>) and MTA (500 mg/m<sup>2</sup>) every 21 days. Responses have been reported in this study, but it is too early to determine response rates.

The Panel agreed that MTA had shown activity in 1<sup>st</sup> line NSCLC, but that additional efficacy and safety data were needed before strategic discussions could be made, given the competition in this indication.

Because the MTA combination Phase 1 studies with cisplatin will be completed prior to combination studies with other possible combination agents, the combination of MTA and cisplatin may offer a means of securing the most rapid route to registration in 1<sup>st</sup> line NSCLC. The advisors, however, generally did not favor proceeding with this combination. Carboplatin was the favored combination agent, although a number of combinations including carboplatin Taxol, cisplatin Taxol, gemcitabine cisplatin and cisplatin Taxotere are currently being compared in the big ECOG study. Despite the lack of phase III data, carboplatin/Taxol is a broadly accepted regimen (described by some as efficacious and easy to administer). These combinations have response rates of the order of 40 to 60% and hence have established a fairly high hurdle rate for an MTA combination. The advisors felt that the MTA/cisplatin combination would have to have significant safety and/or efficacy advantages to be adopted in the marketplace in preference to these regimens. In Phase 2 studies, it would be critical to demonstrate a reasonable and acceptable safety profile, a comparable response rate to these regimens and a median survival of greater than one year before proceeding to Phase 3. Days of hospitalization due to complications of chemotherapy was suggested as an endpoint (possibly a tertiary endpoint). There was concern expressed regarding possible nephrotoxicity of an MTA/cisplatin combination when administered the same day. The possible renal toxicity of MTA is being investigated further in several studies.

The comparator for 1<sup>st</sup> line NSCLC studies will depend on the outcome of ODAC's review of Taxol on March 20 (Taxol + cisplatin, NSCLC) and results of the ongoing ECOG study. (Note: Taxol was approved in combination with cisplatin for front line

NSCLC.) MTA + GEMZAR was suggested as a combination for future evaluation, although Jim Carmichael expressed concerns about the dose intensity of the gemcitabine in the MTA plus Gem phase I study. This combination will probably need further evaluation in a phase I setting before taking it into phase II.


Biomarker studies were suggested as a means of stratifying the population and discriminating between patient groups. Particular subgroups could then be selected for MTA treatment to determine if there was a distinct advantage for MTA. Such studies could be conducted in parallel with other evaluations.

From a strategic standpoint, the Panel agreed that 1<sup>st</sup> line NSCLC studies were not a high priority. There was more enthusiasm for pursuing 2<sup>nd</sup> line NSCLC as an immediate registration strategy, and for generating additional data in 1<sup>st</sup> line that would be analyzed for subsequent decision-making.

If one were to proceed in a front-line setting with MTA plus Gem, the accrual assumptions of 1 year to enroll 600 patients were considered reasonable assuming encouraging Phase I data. Assuming combination MTA + cisplatin, studies would not begin enrollment until Q1 99, with submission/approval Q401/Q302. This assumes initial submission with interim data (TTP data on one-half of the patients), with remaining TTP and survival data made available to reviewers as it is available.

### **Breast Cancer**

#### *Marketing*



#### ***Breast Cancer - 2<sup>nd</sup> line***

The response rate in a single Phase 2 study (JMAG) that involved a heterogeneous population (i.e. including patients treated in the metastatic setting previously) was 33% (1 CR, 9 PR). Some of the patients in this study had failed an anthracycline or taxane. A second Phase 2 study (JMBP) in anthracycline failures is ongoing. Responses have been

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.